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Background: The role of components of the Hippo signaling pathway in mediating pathological cardiac hypertrophy is
incompletely understood.
Results: Genetic ablation ofMst2 reduces pathological cardiac hypertrophic response in adult mice.
Conclusion:Mst2 regulates stress-induced cardiac hypertrophy by modulating the Raf1-ERK1/2 pathway.
Significance:Mst2 might become a novel therapeutic target to reduce pathological hypertrophy.
The Hippo signaling pathway has recently moved to center
stage in cardiac researchbecause of its key role in cardiomyocyte
proliferation and regeneration of the embryonic and newborn
heart. However, its role in the adult heart is incompletely under-
stood. We investigate here the role of mammalian Ste20-like
kinase 2 (Mst2), one of the central regulators of this pathway.
Mst2/ mice showed no alteration in cardiomyocyte prolifer-
ation. However,Mst2/mice exhibited a significant reduction
of hypertrophy and fibrosis in response to pressure overload.
Consistently, overexpression of MST2 in neonatal rat car-
diomyocytes significantly enhanced phenylephrine-induced
cellular hypertrophy. Mechanistically, Mst2 positively modu-
lated the prohypertrophic Raf1-ERK1/2 pathway. However,
activation of the downstream effectors of the Hippo pathway
(Yes-associated protein) was not affected by Mst2 ablation. An
initial genetic study inmitral valve prolapse patients revealed an
association between a polymorphism in the humanMST2 gene
and adverse cardiac remodeling. These results reveal a novel
role of Mst2 in stress-dependent cardiac hypertrophy and
remodeling in the adult mouse and likely human heart.
Cardiac hypertrophy is a key pathological process in the
development of heart failure (1). It is believed that in the adult
heart, enlargement of cardiomyocytes is the major mechanism
involved in hypertrophy (2) rather than cellular proliferation.
However, recent studies have suggested that in both human and
mouse, cardiomyocytes have the capacity to regenerate (3, 4).
Thus, characterization of molecules that are involved in regu-
lating cellular proliferation in the context of cardiac hypertro-
phy is an important focus of study.
The emerging Hippo signaling pathway has been regarded as
the key regulator of cell proliferation and organ size control.
Ablation ofDrosophila hippo results in increased proliferation,
resistance to apoptosis, and organ enlargement (5). The mam-
malian orthologs of hippo are mammalian ste-20-like kinase 1
(Mst1)3 andMst2. Conditional ablation of bothMst1 andMst2
in mouse hepatocytes (6) and intestinal epithelium (7) resulted
in massive cellular proliferation, increased organ size, and
development of multifocal carcinoma. In both models, reduc-
tion in Yes-associated protein (YAP) phosphorylation (the
mammalian ortholog of yorkie), and consequently its nuclear
translocation, appeared to be the responsible mechanism.
TheHippo pathway is also involved in regulating cardiomyo-
cyte proliferation during embryonic development and in neo-
nates. Ablation of Salvador in mouse cardiomyocytes, which
effectively reduced both Mst1 and Mst2 function, resulted in
enhanced cardiomyocyte proliferation during embryonic
development and in newborn mice (8). Moreover, overexpres-
sion of constitutively active YAP in the heart resulted in
enhanced cardiomyocyte proliferation in embryonic and new-
bornmice, whereas YAP ablation caused a significant reduction
of cardiomyocyte number, leading to embryonic lethality (9,
10). However, the precise role of the mammalian Hippo
orthologs in the adult heart is not clear. Recent studies have
described Mst1 as a regulator of apoptosis (11, 12) and
autophagy (13) in the heart. However, the role of Mst2 in adult
heart is not known. Here, we found a novel role for Mst2 in
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modulation of the prohypertrophic Raf1-ERK1/2 pathway in
the adult mouse heart and likely in human heart.
EXPERIMENTAL PROCEDURES
AnimalModel—Micewith targeted deletion of theMst2 gene
were used in this study (14). We used 8–10-week-old male
Mst2/ mice for pressure overload induced hypertrophy
experiments. Mice were maintained on 129Sv/J  C57Bl/6
genetic background. Age- and sex-matched wild type litter-
mates were used as controls. Animal studies were performed in
accordance with the United Kingdom Animals (Scientific Pro-
cedures)Act 1986 andwere approved by theUniversity ofMan-
chester Ethics Committee.
Human Heart Tissues—Heart extracts from human heart
failure and normal subjects were obtained from Asterand, who
obtained informed consent for the use of human tissue samples
and approval by theUnitedKingdomHumanTissueAuthority.
In Vivo Hypertrophy Model—Mice were subjected to trans-
verse aortic constriction (TAC) to generate pressure overload-
induced hypertrophy model as described previously (15). TAC
was conducted using a 7-0 silk suture thatwas tied to a 27-gauge
constriction at the aortic arch, which will produce 25–30
mmHg pressure gradient between the left and right carotid
artery.
Echocardiography and Hemodynamic Analyses in Mice—
Mouse echocardiography was conducted using an Acuson
Sequoia C256 system (Siemens) following a protocol described
previously (16). For hemodynamic analysis, we used a 1.4F pres-
sure-volume catheter (SPR-839) and a pressure volume system
(Millar Instruments). Cardiac function was assessed using a
protocol described previously (16).
Plasmid Constructs and Adenoviruses—Plasmids containing
either human wild type Mst2 or mutant Mst2 K56R were a gift
ofDr. JonathanChernoff (17) (Addgene plasmidnos. 12205 and
12206). Adenoviruses were generated using Gateway vector
system (Invitrogen). To generate Mst2 deletion mutants we
amplified Mst2-C (containing amino acids residue 1–277) by
PCR. Fragment was then cloned to pENTR-11 (Invitrogen) to
allow generation of adenoviruses by the Gateway system.
Neonatal Rat Cardiomyocyte Isolation—Neonatal rat car-
diomyocytes (NRCM) and cardiofibroblasts were isolated from
1–3 day old Sprague-Dawley rat neonates using an established
protocol (18). Cells obtained from the digestion of rat neonate
hearts were plated in medium containing 68% DMEM, 17%
medium 199, 10% horse serum, and 5% fetal bovine serum and
incubated for 60 min at 37 °C to allow attachment of cardiac
fibroblasts. Then, supernatants containing cardiomyocytes
were plated on Primaria plates (BD Biosciences) using similar
plating medium containing 1 M BrdU. Neonatal rat cardiofi-
broblastswere used for experiments after at least three passages
of culture in medium containing 10% FBS.
Adult Cardiac Fibroblast Isolation—Adult cardiac fibro-
blasts were isolated fromMst2/ andWTmice. Heart tissues
were digested with 1.5 mg/ml collagenase A (Roche Applied
Science) and 0.15 mg/ml protease (Sigma). Cells were cultured
in DMEM containing 20% FBS prior to experiments.
Cellular Hypertrophy Experiment—For cardiomyocyte hyper-
trophy experiments, NRCM were infected with the indicated
adenovirus for 24 h and then treated with 20M phenylephrine
for 48 h with or without the addition of ERK1/2 inhibitor
FR180204 (Millipore) at a final concentration of 50 M. NRCM
were stained with anti--actinin antibody (Sigma) and the cell
size was then measured using ImageJ software. Brain natri-
uretic peptide (BNP) promoter activation was analyzed using a
BNP-luciferase adenoviral reporter construct (15), and the
luciferase activity was measured using luciferase detection rea-
gent (Promega).
Western Blot, Immunoprecipitation, and Immunofluorescence—
Isolation of total heart protein lysates andWestern blot analysis
were performed using a protocol described previously (16). For
immunoprecipitation, protein extracts were precleared by
incubation with Bio-Adembeads protein AG (Ademtech) for
2 h at room temperature. Beads were separated using a mag-
netic device. Precleared extracts were then incubated overnight
with 5 g of indicated antibody and 20 l of Bio-Adembeads
Protein AG. Beads were recovered using a magnetic device and
washed three times with 500 l of radioimmune precipitation
assay buffer.Washed beadswere resuspended in Laemmli load-
ing buffer and analyzed byWestern blot. Immunofluorescence
analysis was conducted using a standard protocol as described
previously (18).
Histology—Heart tissues were fixed in phosphate-buffered
saline (PBS) containing 4% paraformaldehyde, embedded in
paraffin, and then sectioned at 5-m thickness. Hematoxylin
and eosin and Masson’s trichrome stainings were conducted
using standard procedures.
Measurement of Cardiomyocyte Size andMyocardial Fibrosis—
Cross-sectional cardiomyocyte size was measured on sections
stained with hematoxylin and eosin using ImageJ software
(NIH). We measured 50–100 cells from at least four different
frames in each independent animal (n 6–8 mice per group).
Myocardial fibrosis was measured on Masson’s trichrome
stained sections. At least five randomly chosen frames from
each animal (n 6–7 mice per group) were analyzed.
TUNEL Assay—TUNEL assay to detect apoptosis was con-
ducted on heart sections and cultured NRCM using the in situ
Cell Death Detection kit (Roche Applied Science) following
protocol recommended by the manufacturer. Triple staining
with TUNEL, anti--actinin antibody (Sigma), and DAPI was
performed to confirm apoptosis in myocyte nuclei.
RNA Isolation and Real time RT-PCR—Total RNA was pre-
pared from isolated heart tissue using TRIzol reagent (Invitro-
gen) following the manufacturer’s instructions. We used the
QuantiTect-SYBR Green RT-PCR system (Qiagen) for real
time quantitative RT-PCR analysis. Analysis of gene expression
was performed using the 2Ct method and are presented as
fold induction of target gene transcripts relative to control.
Reactionswere performed in anABI PRISM7700 (Applied Bio-
systems). Primers were purchased from Qiagen (Quantitect
Primer Assay system). Threshold cycle (Ct) values were deter-
mined using the Sequence Detection System software. GAPDH
levels were used as a reference.
Antibodies—The primary antibody to detect Mst2 was
obtained fromAbgent. Antibodies forMst1, ERK1/2, phospho-
ERK1/2 (Thr202/Tyr204), phospho-Raf1 (Ser338), phosphatase
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2A-C, YAP1, and phospho-YAP1 (Ser127) were obtained from
Cell Signaling Technologies. Antibodies for Raf1 and GAPDH
were obtained from Abcam. We used horseradish peroxidase-
labeled secondary antibodies (Cell Signaling) for visualization.
For immunofluorescence and immunohistochemistry, anti--
actinin (Sigma), and anti Ser10 phospho-HH3 (Cell Signaling
Technologies) were used. Anti Ki67 antibody (Abcam) and
anti-phalloidin (Molecular Probes) were also used. We used
Texas Red or FITC-labeled secondary antibodies (Jackson
ImmunoResearch Laboratories) for visual detection.
Mitral Valve Prolapse Patients—We studied patients with
clinically severe mitral regurgitation due to mitral valve pro-
lapse. Patients with any other valvular diseases with the excep-
tion of mild tricuspid valve regurgitation were excluded. We
also excluded patients with coronary artery disease, severe
heart failure (New York Heart Association IV), uncontrolled
hypertension (blood pressure160/90mmHg), significant res-
piratory disease, renal impairment (creatinine 150 mmol/li-
ter) and peripheral vascular disease. Patients were recruited
from the Cardiovascular Department at South Manchester
University Hospital. The study protocol was approved by the
local Research Ethics Committee, and all patients gave written
informed consent. Symptoms were evaluated using the New
York Heart Association Classification.
Echocardiography of Mitral Valve Prolapse Patients—All
patients underwent trans-thoracic echocardiography and
Doppler examination (Sonos 5500, Phillips Medical, Eind-
hoven, The Netherlands). All measurements were performed
according to the American Society of Echocardiography guide-
lines (19). Regurgitant volume and fraction were measured
using the volumetric method (20). Left ventricular mass was
calculated using theDevereuxmethod (21) and indexed to body
surface area. Left ventricular volumes and ejection fraction
were calculated using the modified Simpson’s biplane method.
Polymorphism Detection—Genomic DNA was extracted
from peripheral blood using the QIAamp DNA blood isolation
kit (Qiagen). Polymorphismswere detected usingTaqManSNP
genotyping assay (Applied Biosystems) following the protocol
recommended by themanufacturer. Reactions were performed
in an ABI PRISM 7700 real time PCR machine.
3-UTR Assay—The 1.2-kb 3-UTR sequence of human
MST2 genewas PCR-amplified and inserted into the pMirGlo
Dual-Luciferase vector (Promega) downstream of the lucif-
erase gene. The effect of 3-UTR sequence insertion was ana-
lyzed in primary human fibroblast cells (obtained from Invit-
rogen). 106 cells were cultured in 24-well plates in DMEM
supplemented with 10% FBS. 2 g of reporter construct was
transfected using Lipofectamine 2000 reagent (Invitrogen)
following the manufacturer’s instructions. Luciferase activ-
ity was examined after 24 h of transfection. The Renilla lucif-
erase activity was also examined for normalization of trans-
fection efficiency.
Data Analysis—Data are expressed as mean	 S.E. and ana-
lyzed using the Student’s t test or one-way analysis of variance
followed by post hocmultiple comparison test where appropri-
ate. A p value
 0.05 was considered significant.
RESULTS
Ablation of Mst2 Alone Did Not Alter Cell Proliferation in
Mouse Heart—To investigate the role of Mst2 in the heart, we
analyzed mice with genetic ablation of the Mst2 gene (Mst2/),
which resulted in complete absence of this protein in the heart
(Fig. 1A). Because inhibition of Hippo pathway in embryonic
hearts resulted in increased cardiomyocyte proliferation (8), we
therefore analyzed cardiomyocyte proliferation in Mst2/
neonatal hearts. We examined hearts from 3-day-old WT and
Mst2/ neonates and stained them with markers of cell mito-
sis: phospho-Ser10 histone H3 (pHH3). We found that there
was no difference in the level of pHH3-positive cells between
WT andMst2/ neonates (Fig. 1, B and C). In addition, anal-
ysis of heart weight/body weight ratio (HW/BW) showed that
there was no difference in cardiac size between WT and
Mst2/ neonates (Fig. 1D). We also examined pHH3 expres-
sion in adult hearts. We did not detect any cardiomyocytes
positive for pHH3 expression in Mst2/ or WT hearts (Fig.
1E). Consistently, HW/BW ratio was not different between
Mst2/ andWT adult hearts (Fig. 1F). As positive controls for
this analysis, we performed pHH3 immunostaining in intes-
tines (Fig. 1G). Taken together, our data indicated that genetic
knock-out ofMst2 did not alter cardiomyocyte proliferation in
either newborn or adult heart.
Cardiac Mst2 Level Was Elevated in Pathological Conditions—
To assess cardiac Mst2 expression level in pathological condi-
tions, we subjected wild type mice to TAC to induce pressure
overload. Two weeks after TAC treatment the heart weight/
tibia length ratio was significantly increased (Fig. 2A). Western
blot analysis showed that expression of Mst2 was elevated by
2 folds (Fig. 2,B andC), suggesting thatMst2may be involved
in the regulation of pathological hypertrophy.
To assess whether Mst2 expression is also up-regulated in
human heart failure, we analyzed MST2 expression in failing
human hearts. In keeping with the data frommouse model, the
MST2 level was elevated by almost 2-fold in failing human
hearts (Fig. 2D), further emphasizing the importance of this
protein during pathological processes.
To determine the cell specificity, we examinedMst2 expres-
sion in cardiomyocytes and cardiofibroblasts isolated from rat
neonatal hearts. Using immunofluorescence, we found that
MST2 was present in both cell types (Fig. 2E). Moreover, in
response to phenylephrine treatment (20M, 48 h), there was a
trend of increased Mst2 expression in cardiomyocytes by1.5
fold (p 0.09, Fig. 2F).
Genetic Ablation of Mst2 Reduced Pathological Hypertrophy
and Fibrosis in Response to Pressure Overload—To further
study the role of Mst2 in pathological condition, we subjected
Mst2/ mice to TAC for 2 weeks. Mst2/ mice showed a
significantly less hypertrophic response comparedwithWT lit-
termates (30% increased of heart weight/tibia length ratio in
Mst2/ versus50% increase inWT, Fig. 3,A andB). Further-
more, the expression of hypertrophic markers such as BNP and
atrial natriuretic peptide were significantly lower in Mst2/
mice compared with wild type following TAC (Fig. 3, C andD).
Consistently, analysis of histological sections revealed less
cardiac remodeling inMst2/mice. Twoweeks after TAC, we
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found that the cardiomyocyte cross-sectional area was signifi-
cantly smaller inMst2/mice compared withWT littermates
(Fig. 3, E and F). Equally important, Mst2/ mice also dis-
played significantly less cardiac fibrosis as indicated by Mas-
son’s trichrome staining and the level of collagen 1 and 3
expression (Fig. 3, G–J). Together, these data suggest a key
role of Mst2 during pathological hypertrophy and cardiac
remodeling.
Echocardiographic assessment revealed that the ventricular
wall thickness ofMst2/mice was significantly thinner com-
pared with WT following TAC (Fig. 4A). In addition,Mst2/
mice displayed smaller left ventricular (LV) end diastolic
dimension and lower LV mass/body weight ratio after TAC
(Fig. 4, B and C). These data support the finding thatMst2/
displayed a reducedhypertrophic response.However, no differ-
ence in ejection fraction was observed between WT and
Mst2/mice (Fig. 4D).
Using a pressure-volume system, we examined the hemody-
namic parameters such as dP/dt max, dP/dt min, and end sys-
tolic pressure volume relationship.We did not observe any dif-
ference in all the contractility parameters tested between WT
and Mst2/ mice, suggesting that there was no alteration in
cardiac function in both groups of mice after 2 weeks of TAC
(Fig. 4, E–G). It is important to note that the left ventricular
systolic pressure was not different between Mst2/ and WT
after TAC, suggesting a similar degree of pressure overload
between these groups (Fig. 4H).
Apoptosis Level—In non-cardiac cells, Mst2 has been
described as an important regulator of apoptosis (22). We
therefore analyzed apoptosis level in the hearts following TAC.
We observed a reduction in the number of apoptotic nuclei in
Mst2/mice after TAC compared with controls as indicated
by TUNEL staining (Fig. 5, A and B). These data are consistent
with previous reports which showed that Mst1, the isoform of
Mst2, is a positive modulator of apoptosis (11, 12).
To further investigate the role ofMst2 in cardiomyocytes, we
generated an adenovirus to overexpress Mst2 in NRCM (Fig.
5C). Using TUNEL assay, we found a consistent data with the in
vivo observation, in which NRCM overexpression resulted in
higher level of apoptosis in NRCM (Fig. 5, D and E).
Fibroblast Proliferation Rate—Fibroblasts play an important
role during cardiac remodeling and fibrosis. Because there was
FIGURE 1. Analysis of cardiomyocyte proliferation in Mst2/ hearts. A, expression of MST2 was completely ablated in Mst2/ hearts as indicated by
Westernblot.B, immunostainingofheart sections fromWTandMst2/neonates (3daysof age). Sectionswere stainedwithanti--actinin (red), anti-phospho-
HH3 (green), and DAPI (blue) (scale bars, 50 m). C, no difference in the number of pHH3-positive cells between WT andMst2/ neonates was observed. D,
quantification of heart weight/body weight ratio showed that there was no difference in cardiac size between WT andMst2/ neonate hearts. E, immuno-
staining of heart sections fromWT andMst2/mice stained with anti--actinin (red), anti-phospho-HH3 (green), and DAPI (blue) (scale bars, 50 m). F, heart
weight/body weight ratio was not different between WT and Mst2/ adult mice. G, immunofluorescence analysis using pHH3 antibody in small intestine
sections as positive control of this assay. The results showed that pHH3 staining was able to detect proliferating cells (arrows indicate pHH3-positive cells).
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a significant difference in the level of fibrosis betweenWT and
Mst2/ mice, it is important to analyze whether fibroblasts
proliferation rate is different between these mice. We isolated
adult cardiac fibroblasts fromWTandMst2/ and performed
Ki67 staining (marker of mitosis) and BrdU incorporation
assay. Results shown in Fig. 6,A–D, suggested that there was no
difference in proliferation rate betweenWT andMst2/ adult
cardiac fibroblasts.
Cellular Mechanisms of Mst2 Mediated Raf1/ERK1/2
Regulation—Mst2 has been described previously to form a
molecular interaction with Raf1 in COS-1 cells (23). Raf1 is an
important progrowth and survival kinase that modulates the
mitogen-activated protein kinase (MAPK) pathway (24). We
therefore examined whether Mst2 interacts and modulates
Raf1 in cardiomyocytes. Immunoprecipitation analyses in iso-
lated cardiomyocytes (Fig. 7A) and mouse whole heart lysates
(Fig. 7B) showed that Mst2 and Raf1 were co-immunoprecipi-
tated, strongly suggesting a physical interaction between these
molecules.
To further analyze the regulatory mechanism of the Mst2-
Raf1 signaling complex in cardiomyocytes, we generated an
adenovirus expressing inactive mutant form of Mst2 (Mst2
K56R mutant) (17). As shown in Fig. 7, C–E, overexpression of
wild type Mst2 enhanced the level of Raf1 phosphorylation in
cardiomyocytes. We also detected increased phosphorylation
of prohypertrophic kinase ERK1/2, which is a downstream
effector of Raf1. In contrast,Mst2 K56Rmutant overexpression
failed to induce phosphorylation of Raf1 and ERK1/2, suggest-
ing that the kinase activity ofMst2 is likely to be responsible for
the activation of Raf1 and ERK1/2.
To investigate the importance of Mst2-Raf1 interaction, we
generated Mst2 truncation mutant. We generated adenovirus
expressingMst2-C (containing amino acid residues 1–277) by
deletion of amino acids 288–491 and removing the Salvador
RASSF Hippo (SARAH) domain at the C terminus region of
Mst2. Expression of this mutant molecule was detected by
Western blot (Fig. 7F). The immunoprecipitation experiment
showed that this molecule did not interact with Raf1 in car-
diomyocytes (Fig. 7G). Surprisingly, when we overexpressed
Mst2-C in NRCM, we still found increased level of ERK1/2
phosphorylation which was comparable with those of Mst2
WT-overexpressing cells (Fig. 7H). This data suggested that
protein interaction between Mst2-Raf1 was not necessary in
the regulation of Raf1/ERK1/2 by Mst2.
Previously, it has been reported that Mst2 positively regu-
lated Raf1 throughmodulation of phosphatase 2A (PP2A) (25).
Therefore, we examined the expression of the catalytic C sub-
unit of PP2A inNRCM-overexpressingMst2.We founda trendof
increasedPP2A-C inMst2-overexpressingcardiomyocytes (Fig. 7,
I–J), which is consistent with previously published observations
(25). This indicates that PP2A might be involved in Mst2-depen-
dent regulation of Raf1/ERK1/2 in cardiomyocytes.
FIGURE2.CardiacexpressionofMST2 inpathological conditions.A, wild typemicewere subjected toTAC to inducepressureoverloadcardiachypertrophy.
Heart weight/tibia length ratio was significantly increased in the TAC group (n 5–10 in each group; **, p
 0.01 versus sham). B, Western blot analysis ofMst2
expression in mouse heart lysates following TAC or sham operation. C, analysis of band density showed a significant increase in MST2 level in hypertrophic
hearts (n  5;**, p 
 0.01). D, MST2 expression in humans with end-stage heart failure (HF) was detected by Western blot. Quantification of band density
showed thatMST2 level was elevated in failing hearts (n 3 in each group; *, p
 0.05). E, immunofluorescence analysis ofMST2 expression in cardiomyocytes
and cardiofibroblasts isolated from rat neonatal hearts. F, Westen blot and band density quantification of MST2 expression in neonatal rat cardiomyocytes
following phenylephrine (PE) treatment (20 M, 48 h). Con, control.
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Mst2 Overexpression Enhanced Phenylephrine-induced Car-
diomyocyte Hypertrophy—We performed an in vitro model of
cardiomyocyte hypertrophy by treating NRCM with phenyl-
ephrine (20 M, 48 h). Mst2 overexpression significantly
enhanced cardiomyocyte size basally by 19% and increased
phenylephrine-induced cardiomyocyte hypertrophy from
30% in control to42% inMst2-overexpressing cells as indi-
cated by cell surface areameasurements (Fig. 8,A andB).More-
over, using an adenovirus mediated BNP-luciferase reporter
construct, we also detected significantly higher expression of
the hypertrophic marker BNP in Mst2-overexpressing cells
(Fig. 8C).
To ascertain that the Mst2 prohypertrophic action was
through regulation of the ERK1/2 pathway, we treated car-
diomyocytes overexpressing Mst2 with ERK1/2-specific inhib-
itor FR180204. This inhibitor has been shown to have a potent
and specific inhibition of ERK1 (IC50  510 nM) and ERK2
(IC50 330 nM) (26). As shown in Fig. 8, B and C, inhibition of
ERK1/2 reduced the hypertrophic response of Mst2-overex-
pressing myocytes to the level comparable with control cells,
strongly indicated the implication of ERK1/2 in this process.
We then analyzed the effect of expressing Mst2 K56R
mutant. Cell size analysis showed that overexpression of Mst2
K56R mutant significantly reduced cardiomyocyte size at basal
FIGURE 3. In vivomodel of pressure overload inducedhypertrophy inMst2/mice.A, hearts fromWT andMst2/mice following TAC (2weeks) or sham
operation. B, analysis of HW/tibia length ratio showed significant reduction of hypertrophic response inMst2/mice (n 7–8 in each group; *, p
 0.05; **,
p 
 0.01; ***, p 
 0.001). Expression of hypertrophic markers were as follows: BNP (C) and atrial natriuretic peptide (ANP; D) were detected using real time
RT-PCR. Values indicate fold change of expression after normalizationwith GAPDH level (n 5–7 in each group; *, p
 0.05). Histological sections stainedwith
hematoxylin and eosin (E) and quantification of cardiomyocyte cross-sectional area (F) showed smaller cardiomyocyte size in Mst2/mice after TAC (scale
bars, 20 m; ***, p
 0.001). Masson’s trichrome staining (G) and quantification of fibrotic area (H) indicated significantly less fibrosis inMst2/mice (*, p

0.05). Expressions of collagen 1 (I) and collagen 3 (J) were detected using real time RT-PCR. Values indicate fold change of expression following normalization
with GAPDH level (n 5–7 in each group; *, p
 0.05).
FIGURE4.Echocardiographyandhemodynamicanalysis.Ventricularwall thickness (averageofposterior and interventricular septumwall thickness) (A) and
left ventricular end diastolic diameter (B) inMst2/mice compared withWT after TAC or sham operation (n 7–8; *, p
 0. 05). C, left ventricular mass/body
weight ratiowas significantly higher inWTmice (n 7–8; *, p
 0.05). However, therewere nodifferences in cardiac contractility indices as indicated byD. End
systolic pressure volume relationship (ESPVR), ejection fraction (E), dP/dt max (F), and dP/dt min (G). H, left ventricular systolic pressure was significantly
elevated following TAC in both genotypes; however, no difference between WT and knock-out was observed basally or after TAC.
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condition by15%. Interestingly, therewas no difference in the
hypertrophic response against phenylephrine stimulation (Fig.
8D).
Mst2 Modulated Raf1-ERK1/2 Pathway in Pathological
Conditions—Our cellular model showed that in cardiomyo-
cytes Mst2 was linked to the prohypertrophic MAPK pathway
via Raf1. However, Mst2 has been widely known as a central
component of the Hippo signaling pathway (5). We therefore
focused on these two pathways to uncover themolecularmech-
anism responsible for the reduce response to hypertrophic
stress observed inMst2/mice.
Our data presented in Fig. 9 indicated that the MAPK path-
way was modulated by Mst2. We investigated whether Mst2
modulates Raf1 following pathological stress. Western blot
analysis showed that Raf1 phosphorylation was significantly
reduced inMst2/ compared withWT following TAC (Fig. 9,
A and B). Because Raf1 is an upstream activator of the pro-
hypertrophic kinase ERK1/2 (24, 27), we also examined activa-
FIGURE 5.Detection of apoptotic cells inMst2/ hearts and in isolated cardiomyocytes overexpressingMst2. A, examples of TUNEL staining to detect
apoptotic cells. Triple staining was performed: TUNEL (green), DAPI (blue), and -actinin (red). Arrows indicate TUNEL-positive nuclei. B, calculation of TUNEL-
positive nuclei revealed that Mst2/ mice exhibited a reduced level of apoptosis compared with WT following TAC (n  4–5; *, p 
 0.05). C, immunoblot
analysis showing dose-dependent expression ofMst2 in NRCM following infectionwith adenovirus expressing humanMst2 (Ad-Mst2). Adenovirus expressing
LacZ (Ad-LacZ) was used as a control. (MOI, multiplicity of infection).D, representatives TUNEL staining in neonatal rat cardiomyocytes treatedwith adenovirus
expressing Mst2 or LacZ (control). E, quantification of TUNEL-positive nuclei showed more apoptotic cells in cardiomyocytes expressing Mst2 (*, p
 0.05).
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tion of these kinases by Western blot. Data presented in Fig. 9,
A and C, showed that ablation of Mst2 significantly reduced
phosphorylation of ERK1/2 following TAC.
YAPActivationWasNotAffected inMst/Hearts Following
TAC—We then analyzed whether the Hippo signaling pathway
was differently regulated in Mst2-deficient mice. Mst1 expres-
sion was elevated following TAC; however, no difference was
observed between WT and Mst2/ mice (Fig. 10, A and B).
Consistently, we observed similar levels of YAP phosphoryla-
tion in post-TAC heart tissue lysates between KO andWT (Fig.
10C). YAP is known as the downstream effector of Mst1/2 and
the major components of the Hippo pathway. Therefore, these
results suggest that in adult cardiac cells Mst2 ablation did not
affect the activation of YAP following stress.
A Polymorphism in the Human MST2 Gene Was Associated
with Adverse Left Ventricular Remodeling in Mitral Valve Pro-
lapse Patients—We conducted an initial study to investigate
whether genetic variation in the human MST2 gene is associ-
ated with cardiac remodeling in patients with mitral valve pro-
lapse.We analyzed single nucleotide polymorphisms (SNPs) in
the human MST2 gene in 62 mitral valve prolapse patients.
Based on sequence analysis, we focused our study on two SNPs
located in the regulatory region of the human MST2 gene: (i)
rs3019294, which is located at the promoter region and may
affect the binding of transcription factors; ii) rs10955176, which
is located at the 3-untranslated region (3-UTR) sequence and
may interfere with the binding of human micro RNAs.
Although we found no association between rs3019294 with all
parameters tested (Table 1), we did identify that rs10955176
was significantly associated with hypertrophic parameters such
as LVmass and wall thickness (Table 2). This SNP is an A-to-G
substitution located 214 base pairs downstream of the stop
codon; therefore, we refer to this SNP as 214A/G polymor-
phism. Patients carrying the GG allele showed greater LVmass
and wall thickness, despite similar level in the indices of mitral
regurgitation and LV function.
To investigate whether this SNP regulates gene expression,
we isolated thewhole 3-UTR sequence (1.2 kb) frompatients
carrying the GG or AA allele and cloned them into a luciferase-
based reporter cassette (Fig. 11A). Expression of Renilla lucif-
erase driven by a constitutively active promoterwithin the same
construct was used to control transfection efficiency. In pri-
mary human skin fibroblasts, we found that the reporter con-
struct carrying the 214G 3-UTR produced significantly
higher luciferase signal than that carrying the 214A 3-UTR
FIGURE 6. Analysis of adult cardiac fibroblast proliferation rate. Adult cardiac fibroblasts were isolated from Mst2/ and WT littermates. A, immuno-
stainingwithmitosismarker Ki67.Arrows indicate Ki67-positive nuclei. B, quantification of Ki67-positive cells showed that therewas nodifference betweenWT
andMst2/ cardiac fibroblasts.C, fibroblastswere treatedwith 1:100dilutionof BrdU-labeling reagent (Invitrogen) for 24h, and thepresenceof BrdU-positive
cells was determined by immunostaining. D, quantification of BrdU-positive cells supported the Ki67 staining data that there was no difference in the
proliferation rate between WT andMst2/ cardiac fibroblasts.
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(Fig. 11B). This suggests that patients carrying theGGgenotype
may have more Mst2 expression.
DISCUSSION
This study demonstrates that Mst2 plays a key role in medi-
ating stress-induced pathological hypertrophy and remodeling
in the adult heart. Mice with genetic deletion of the Mst2 gene
displayed a significant reduction in cardiac hypertrophy, apo-
ptosis, and fibrotic remodeling following pressure overload.
Conversely, overexpression of Mst2 in cardiomyocytes
enhanced adrenergic-induced cardiomyocyte hypertrophy and
fetal gene activation.
Interestingly, in ourmodel, the ablation ofMst2 did not alter
activation of YAP and hence cardiomyocyte proliferation. One
possible explanation is that in the absence of Mst2, Mst1 con-
FIGURE 7.Mst2 regulates Raf1 and ERK1/2 activation. A, immunoprecipitation analysis of lysates fromNRCM using Raf1 or control (luc, luciferase) antibody (Ab).
Raf1 interacted with Mst2 in NRCM, but no difference in the amount of interacting protein was detected following phenylephrine (PE) stimulation. B, consistently,
immunoprecipitation analysis of total heart lysates fromWT andMst2/ showed that Mst2 was co-precipitated with Raf1. C, immunoblot analysis to detect phos-
phorylated/total Raf1 and phosphorylated/total ERK1/2 in NRCM overexpressing LacZ (control), Mst2, or Mst2 kinase-defective mutant (Mst2 K56R). Band density
quantificationofphospho-Raf1/total Raf1 (D) andphospho-ERK1/2/total ERK1/2 (E) (*,p
0.05;n3–4 independent experiments). E,Westernblot analysis showing
the expressionof truncatedmutantMst2-C. F, immunoprecipitation analysis using Raf1 or control antibody inNRCMoverexpressingMst2-C showed thatmutant
Mst2-C did not interact with Raf1. G, overexpression of mutant Mst2-C enhanced the level of phospho/total ERK1/2. H, representative immunoblots for the
detection of PP2A C subunit in NRCM. I, densitometric analysis showed a trend of higher PP2AC level in NRCMoverexpressingMst2.
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FIGURE 8. Phenylephrine-induced cardiomyocyte hypertrophy model. A, images of NRCM overexpressing Mst2 and control (LacZ) following treat-
ment with 20 M phenylephrine (PE) for 48 h with or without the addition of ERK1/2 inhibitor FR180204 (50 M). Cells were stained with -actinin
antibody to specifically visualize cardiomyocytes. Scale bars, 50m. B, quantification of cell surface area indicated thatMst2 overexpression significantly
enhanced phenylephrine-induced hypertrophic response. (Results were from four independent experiments conducted in triplicate; a minimum of 100
cells were measured per replicate.) (***, p 
 0.001). Treatment with FR180204 reduced the hypertrophic response in Mst2-overexpressing cells to the
level comparable with control cells with the same treatment. C, using adenovirus expressing a luciferase reporter driven by the rat BNP promoter, we
found that Mst2 overexpression increased activation of the BNP promoter both basally and after phenylephrine stimulation (n 8; **, p
 0.01;***, p

0.001). Consistently, treatment with FR180204 abolished the difference in hypertrophic response between Mst2-overexpressing myocytes and control
cells. D, representative images of NRCM-overexpressing Mst2 K56R mutant and the quantification of cell surface area at basal condition and after
stimulation with phenylephrine (***, p 
 0.001).
FIGURE 9.Analysis of Raf1 and ERK1/2 activation during TAC-induced hypertrophy. A, representative Western blots to detect phosphorylated/total
Raf1 and phosphorylated/total ERK1/2 in total heart extracts ofMst2/ andWTmice following TAC. Quantification of phosphorylated/total Raf1 (B) and
ERK1/2 (C) showed that activation of Raf1 and ERK1/2 were decreased in Mst2/ mice during pathological hypertrophy (*, p 
 0.05; n  5–7 in each
group).
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trols and suppresses the activation of YAP as we found that
there was no difference in Mst1 expression between Mst2/
mice and WT controls.
It is also important to note that in adult tissues, the response
toHippo pathway inhibition seems to be cell specific. Induction
of proliferation occurred in cells of epithelial origin such as
hepatocytes (6, 28) and intestinal epithelium (7). In contrast, in
other cell types such as mouse embryonic fibroblasts, inactiva-
tion of Mst1 and Mst2 did not result in increased YAP activity
(6). Our data adds to a growing body of evidence that in adult
cardiomyocytes components of the Hippo pathway may regu-
late alternative pathways. For example, recent studies have
demonstrated that Mst1 regulates apoptosis and autophagy in
the heart (11–13). In addition, overexpression of Lats2, the
downstream target of Mst1, resulted in the reduction of car-
diomyocyte growth and protein synthesis as well as increased
apoptosis (29).
Consistent with previous data, which showed thatMst1 pos-
itively induced cardiomyocyte apoptosis (11, 12), we found that
ablation ofMst2 reduced cardiomyocyte apoptosis level follow-
ing TAC. This process might be important with regard to the
FIGURE 10.Analysis ofMst1 expression andYAPactivation in thehearts duringhypertrophy.A, immunoblot analyses to determine the level ofMST1 and
phosphorylated/total YAP (tYAP). Band density quantification of MST1 normalized to GAPDH level (B) and phosphorylated/total YAP (C) showed that the level
of Mst1 expression as well as activation of YAP were not altered inMst2/mice following TAC (n 5–7 in each group).
TABLE 1
Characteristics ofMVPpatients according to rs3019294polymorphism
LV, left ventricular; dPW, posterior wall thickness at diastole; sPW, posterior wall
thickness at systole; dIVS, interventricular septal wall thickness at diastole; sIVS,
interventricular septal wall thickness at systole. None of the differences are statisti-
cally significant.
Variable CC CT/TT
N 50 12
Gender (male/%) 34 (68%) 10 (83%)
Age (years) 63	 1.3 64	 3.0
Body mass index 25.4	 0.41 25.7	 0.92
Body surface area (m2) 1.83	 0.02 1.88	 0.06
Systolic blood pressure (mmHg) 133	 1.3 138	 2.34
Diastolic blood pressure (mmHg) 76	 1.0 74	 2.2
LV end diastolic dimension (cm) 5.47	 0.10 5.36	 0.26
LV mass (g) 256	 13 278	 32
LV mass index (g/m2) 139	 6.5 150	 19
dPW (cm) 1.15	 0.03 1.23	 0.07
sPW (cm) 1.54	 0.04 1.57	 0.10
dIVS (cm) 1.13	 0.04 1.24	 0.08
sIVS (cm) 1.60	 0.05 1.75	 0.10
Ejection fraction (%) 63	 0.9 61	 2.4
Regurgitation fraction (%) 64	 1.5 63	 3.6
TABLE 2
Characteristics of MVP patients according to MST2  214 G/A
(rs10955176) polymorphism
LV, left ventricular; dPW, posterior wall thickness at diastole; sPW, posterior wall
thickness at systole; dIVS, interventricular septal wall thickness at diastole; sIVS,
interventricular septal wall thickness at systole.
Variable 214 GG 214 GA/AA
N 16 46
Gender (male/%) 13 (81%) 31 (67%)
Age (years) 63	 1.9 63	 1.5
Body mass index 25.5	 0.68 25.4	 0.45
Body surface area (m2) 1.88	 0.03 1.83	 0.03
Systolic blood pressure (mmHg) 137	 1.9 133	 1.4
Diastolic blood pressure (mmHg) 76	 1.8 75	 1.0
LV End diastolic dimension (cm) 5.70	 0.18 5.34	 0.11
LV mass (g) 306	 24 244	 13a
LV mass index (g/m2) 164	 13.8 133	 6.8a
dPW (cm) 1.31	 0.06 1.11	 0.03a
sPW (cm) 1.73	 0.05 1.49	 0.04a
dIVS (cm) 1.21	 0.07 1.13	 0.04
sIVS (cm) 1.80	 0.09 1.58	 0.05b
Ejection fraction (%) 61	 2.3 63	 0.9
Regurgitant fraction (%) 65	 3.1 63	 1.6
a p
 0.05.
b p 0.05.
FIGURE 11. Functional analysis of the human MST2  214G/A polymor-
phism. A, schematic diagram of the luciferase constructs used for the exper-
iment. The 1.2-kb 3-UTR of the humanMST2 gene carrying either214 G or
A allele were inserted downstream of the luciferase-coding region. The
expression of Renilla luciferase was used as a control for transfection effi-
ciency. B, analysis using human primary fibroblasts indicated that the 3-UTR
bearing G allele produced significantly higher luciferase (luc) compared with
3-UTR with A allele. (*, p
 0.05).
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difference in fibrosis level betweenWTandMst2/mice after
TAC. Although cardiac fibrosis levels were significantly less in
Mst2/mice, we did not observe any difference in the cardiac
fibroblast proliferation rate between knock-out and wild type.
This suggests that the difference in fibrotic remodeling might
be caused by an increased in reparative fibrosis due to the
higher apoptosis level in WT mice.
Our mechanistic analyses suggest that Mst2 might regulate
cardiomyocyte hypertrophic growth through modulation of
Raf1 kinase, which subsequently activates prohypertrophic
ERK1/2 kinases. TheRaf1/ERK1/2 signaling cascade is involved
in regulating cardiomyocyte growth as evidenced by observa-
tion in cultured cells as well as transgenic animals (24, 27, 30). It
appears that the Mst2 kinase domain plays a key role in this
process because the kinase inactive (K56R) mutant form of
Mst2 failed to activate Raf1. However, it seems that inhibition
of physical interaction between Mst2-Raf1 does not affect the
activation of Raf1 and ERK1/2 by Mst2 because expression of
mutantMst2-C, which does not interact with Raf1, is still able
to induce ERK1/2 phosphorylation. However, analysis of phos-
phatase 2A catalytic C subunit (PP2A-C) expression indicates a
possible involvement of this molecule in the regulation of Raf1
byMst2, which is in agreement with previous published data by
Kilili et al. (25). Indeed, further studies are still needed to pre-
cisely understand the regulatorymechanismof Raf1/ERK1/2 by
Mst2. For example, it is not yet clear how Mst2 expression
induces PP2A-C expression andwhy an intact kinase domain is
needed in the modulation of Raf1/ERK1/2 activation.
Our data also point toward a potentially relevant role of an
MST2 polymorphism in human heart remodeling. Our initial
study suggested a possible novel association between a poly-
morphism at the 3-UTR of the humanMST2 gene (214G/A)
with adverse remodeling in patients with mitral valve prolapse
regardless of the regurgitant fraction. In addition, we show a
molecular mechanism by which the polymorphism might be
operative. Using a luciferase reporter system, we provide evi-
dence that the polymorphism affects luciferase expression. Our
data imply that individuals carrying a homozygous G allele may
have higher Mst2 levels and hence exhibit more pronounced
LV hypertrophy and remodeling, in agreement with our in vivo
and in vitromodels. However, these data should be regarded as
preliminary, due to the relatively low number of patients used
in this study, and thus, it should be tested in larger studies.
Overall, our results indicate that the Mst2-Raf1 signaling
complex is a key regulator of pathological hypertrophy and
remodeling in the heart. This complex mediates important
downstream pathways in cardiomyocytes. Mst2 might there-
fore be a novel therapeutic target to reduce hypertrophy and
adverse remodeling. Future studies need to be done to identify
and develop novel inhibitor of this kinase and to test the effect
on pathological hypertrophy.
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